XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENTS (Tables)
 3 Months Ended
Mar. 31, 2025
SEGMENTS [Abstract]  
Summarized Financial Information Concerning Reportable Segments Summarized financial information concerning reportable segments is shown in the following tables:
            
Three Months Ended March 31, 2025
(in thousands)
  
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Total
 
Revenues
 $113,716   $1,050   $114,766 
               
Cost of product revenue
  53,057    648    53,705 
               
Research and development
  826      -       826 
               
Plasma center operating expenses
    -       1,286    1,286 
               
Selling, marketing and distribution
  6,044      -       6,044 
               
Depreciation and amortization expense
  25      -       25 
               
General and administrative expense
  8,495      -       8,495 
               
Other expense, net
  (64)      -       (64) 
               
Income (loss) before taxes
  45,205    (884)    44,321 
               
Expenditures for additions to long-lived assets
  4,699    21    4,720 
Total assets
  330,091    27,644    357,735 
               
Reconciliation of revenues:
              
Segment revenue
           $114,766 
License revenue
            36 
Consolidated revenues
           $114,802 
               
Reconciliation of selling, general and administrative expense:
              
Segment selling, marketing and distribution expense
           $6,044 
Segment general and administrative expense
            8,495 
Corporate general and administrative expense (a)
            9,540 
Consolidated selling, general and administrative expense
           $24,079 
               
Reconciliation of income (loss) before taxes:
              
Segment income before taxes
           $44,321 
License revenue
           36 
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)
            (1,975) 
Unallocated interest income
            608 
Corporate general and administrative expense (a)
            (9,540) 
Consolidated income before taxes
           $33,450 
               
Reconciliation of total assets:
              
Total segment assets
           $357,735 
Corporate (b)
            152,834 
Consolidated total assets
           $510,569 
 
(a) -
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.
 
(b) -
Primarily consists of cash and deferred tax assets.
            
Three Months Ended March 31, 2024
(in thousands)
  
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Total
 
Revenues
 $80,113   $1,726   $81,839 
               
Cost of product revenue
  40,991    1,776    42,767 
               
Research and development
  451      -       451 
               
Plasma center operating expenses
    -       1,005    1,005 
               
Selling, marketing and distribution
  4,431      -       4,431 
               
Depreciation and amortization expense
  193      -       193 
               
General and administrative expense
  5,351      -       5,351 
               
Other expense, net
  (30)    (1)    (31) 
               
Income (loss) before taxes
  28,666    (1,056)    27,610 
               
Expenditures for additions to long-lived assets
  2,330    17    2,347 
Total assets
  278,331    33,990    312,321 
               
Reconciliation of revenues:
              
Segment revenue
           $81,839 
License revenue
            36 
Consolidated revenues
           $81,875 
               
Reconciliation of selling, general and administrative expense:
              
Segment selling, marketing and distribution expense
           $4,431 
Segment general and administrative expense
            5,351 
Corporate general and administrative expense (a)
            5,857 
Consolidated selling, general and administrative expense
           $15,639 
               
Reconciliation of income (loss) before taxes:
              
Segment income before taxes
           $27,610 
License revenue
           36 
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)
            (3,769) 
Unallocated interest income
            381 
Corporate general and administrative expense (a)
            (5,857) 
Consolidated income before taxes
           $18,401 
               
Reconciliation of total assets:
              
Total segment assets
           $312,321 
Corporate (b)
            38,554 
Consolidated total assets
           $350,875 
 
(a) -
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.
 
(b) -
Primarily consists of cash and deferred tax assets.
Net Revenues According to Geographic Area
Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:
                    
                         
  Three  Months Ended March 31, 2025
    ADMA BioManufacturing      Plasma Centers      Total Segment
Revenue 		     License Revenue      Consolidated Revenue  
United States
$110,609   $85   $110,694   $36   $110,730 
International
 3,107    965    4,072     -        4,072 
Total revenues
$113,716   $1,050   $114,766   $36   $114,802 
                    
                         
  Three  Months Ended March 31, 2024
    ADMA BioManufacturing      Plasma Centers      Total Segment
Revenue 		     License Revenue      Consolidated Revenue  
United States
$76,460   $1,495   $77,955   $36   $77,991 
International
 3,653    231    3,884     -        3,884 
Total revenues
$80,113   $1,726   $81,839   $36   $81,875